Adamas Pharmaceuticals Inc - Strategic SWOT Analysis Review

Adamas Pharmaceuticals Inc - Strategic SWOT Analysis Review

- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – GlobalData’s summarization of the company’s business strategy.
• SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.

Highlights

Adamas Pharmaceuticals Inc (Adamas Pharmaceuticals) discovers, develops and markets therapeutics for treatment of neurological diseases. The company's Gocovri is an amantadine extended-release capsule for the treatment for dyskinesia in patients with Parkinson’s disease. Gocovri is a high-dose, once-daily indication designed to deliver a high level of amantadine in the morning and throughout the day when dyskinesia occurs. It also offers Namenda XR and Namzaric capsules for the treatment of moderate to severe Alzheimer’s dementia disease under an exclusive license agreement with Allergan. The company is investigating ADS-5102 in Phase III clinical trials for the treatment of walking impairment in patients with multiple sclerosis, and ADS-4101 in Phase III clinical trials for the treatment of partial onset seizures in patients with epilepsy. The company markets its products to distributors and specialty pharmacies through its sales force of neurology specialist and in collaboration with partners. Adamas Pharmaceuticals is headquartered in Emeryville, California, the US.
Adamas Pharmaceuticals Inc Key Recent Developments

Nov 23,2021: Supernus Pharmaceuticals announces expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
Sep 13,2021: Adamas Pharmaceuticals and Westwood & Wilshire team up to hire Senior Director, Commercial Quality Assurance
Jun 23,2021: Adamas to Present at Upcoming SVB Leerink CNS Forum
Jun 08,2021: Adamas Pharmaceuticals announces board changes

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note:Some sections may be missing if data is unavailable for the company.